BiotechTube
JLP Health

JLP Health

Vienna, Austria· Est.
jlphealth.com
Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Total funding raised: $1.5M

Overview

JLP Health is a private, pre-clinical stage biotech leveraging a unique forward genetic screening platform to deconvolute drug mechanisms of action and identify novel targets, particularly from natural compounds like Artemisinin. Its lead program is a novel combinatorial therapy for glioblastoma, with clinical trials targeted for 2026, and it has also contributed to research on Crimean-Congo Haemorrhagic Fever. The company employs a hybrid business model of internal therapeutic development and platform services through its affiliates, Acus Laboratories in Germany and Angal Biotechnology in China, supported by seed investment from business angels.

OncologyInfectious Diseases

Technology Platform

Proprietary forward genetic screening platform combining advanced cell engineering (haploid systems via ACUS technology) to mine genome function at single amino acid resolution for target deconvolution and drug discovery.

Funding History

1
Total raised:$1.5M
Seed$1.5M

Opportunities

The high unmet need in glioblastoma and the broad demand for reliable target deconvolution in drug discovery present significant market opportunities.
The strategic joint venture in China provides a direct pathway to develop and commercialize first-in-class medicines in a major global market, leveraging insights from traditional natural compounds.

Risk Factors

Key risks include the pre-clinical stage of its lead asset with a long development timeline, dependence on future fundraising in a tight capital market, and the operational complexity of managing a tri-continental corporate and scientific structure.
Platform validation through successful clinical translation is non-guaranteed.

Competitive Landscape

JLP Health competes with numerous biotechnology companies offering drug discovery platforms (e.g., CRISPR screening, AI/ML target ID) and biopharmas focused on glioblastoma. Its differentiation lies in the single amino acid resolution of its ACUS haploid screening technology and its unique integration of traditional medicine insights with modern genetics.

More companies in Cell & Gene Therapy →More companies in Austria →